Senate Panel Approves Expedited Medical Device Review Bill

| Printer friendly version

(March 11, 2016) The U.S. Senate Health, Education, Labor & Pensions committee approved a bill to expand an expedited review program for FDA approval of certain medical devices. The bill, S. 1077 “A bill to provide for expedited development of and priority review for breakthrough devices,” is aimed at expediting the approval process for ‘breakthrough’ medical devices, and builds on the FDA’s Expedited Access Pathway, which was implemented in 2015.

According to the bill, ‘Breakthrough’ medical devices treat or diagnose life-threatening or irreversible diseases for which no approved alternatives exist, or offer significant advantages over existing technologies. The streamlined review process for these devices would require shorter and smaller clinical trials to show a device’s success, and would implement quicker compliance time-frames. Expedited review would be available to all classes of medical device; currently only class III, or high risk, devices are able to receive expedited review. A similar program is available for FDA approval of drugs designated as “breakthrough therapies.

Some advocacy groups have expressed concerns that patients may be put at risk if the FDA is not thorough enough during the quickened approval process. Proponents of the bill counter that an expedited review process will allow patients more timely access to potentially life-saving devices.

The bill is part of a larger effort by the National Institutes of Health to increase medical research. The NIH hopes that streamlining the review process for revolutionary medical devices will lead to increased private sector investment in medical device research.

 

 

 

Leave a Reply

By using this blog, you agree and understand that no information is being provided in the context of any attorney-client relationship. You further agree and understand that nothing herein is intended to be legal advice. This blog is solely informational in nature, and is not intended as, and should not be used as, a substitute for competent legal advice from a retained and licensed attorney in your state. Knobbe Martens LLP makes no representations or warranties as to the accuracy, completeness, timeliness or availability of the information in this blog. Knobbe Martens LLP will not be liable for any injury or damages relating to your use of, or access to, any such information. Knobbe Martens LLP undertakes no obligation to correct or update information on this blog, which may be incorrect or become incorrect or out of date over time. Knobbe Martens LLP reserves the right to alter or delete content or information on the blog at any time. This blog contains links and references to other websites and publications that you may find of interest. Knobbe Martens LLP does not control, promote, endorse or otherwise have any affiliation with any other websites or publications unless those websites or publications expressly state such an affiliation. Knobbe Martens LLP further has no responsibility for, and makes no representations regarding, the content, accuracy or any other aspect of the information in such websites or publications.